[Perioperative Targeted Therapy for Operable, Early Stage NSCLC]

Area of Science:

• Oncology
• Translational Medicine

Background:

• Non-small cell lung cancer (NSCLC) exhibits significant recurrence rates even in early stages, impacting long-term patient outcomes.
• Recurrence-free survival rates vary significantly by stage, with 5-year rates of 62% (stage IA1), 40.7% (stage IIA), and 28% (stage IIIA) in a German cohort.

Purpose of the Study:

• To review the current status of adjuvant targeted therapy in early-stage NSCLC.
• To discuss the associated diagnostic testing required for targeted therapy selection.
• To provide an outlook on future advancements in this therapeutic area.

Main Methods:

• Review of current literature and clinical practice guidelines.
• Analysis of data regarding adjuvant targeted therapy in NSCLC.
• Discussion of diagnostic strategies for identifying eligible patients.

Main Results:

• Adjuvant targeted therapy, including EGFR inhibitors like osimertinib, is emerging from palliative care into early-stage NSCLC treatment.
• Osimertinib has demonstrated improved overall survival in the adjuvant setting for NSCLC.
• Testing for specific molecular targets is crucial for guiding adjuvant therapy selection.

Conclusions:

• Adjuvant targeted therapy represents a significant innovation for early-stage NSCLC, moving beyond traditional approaches.
• The integration of targeted therapies like osimertinib, supported by appropriate testing, is transforming early-stage NSCLC management.
• Ongoing research and development are expected to further refine and expand adjuvant treatment options for NSCLC.